Pyruvate Oxidation Sustains B Cell Antigen-Specific Activation to Exacerbate MASH.


Journal

bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187

Informations de publication

Date de publication:
15 Nov 2023
Historique:
pubmed: 28 11 2023
medline: 28 11 2023
entrez: 28 11 2023
Statut: epublish

Résumé

B cells play a crucial role in the pathogenesis of metabolic dysfunction-associated steatohepatitis (MASH), a severe form of steatotic liver disease that if persistent can lead to cirrhosis, liver failure, and cancer. Chronic inflammation and fibrosis are key features of MASH that determine disease progression and outcomes. Recent advances have revealed that pathogenic B cell-derived cytokines and antibodies promote the development of MASH. However, the mechanisms through which B cells promote fibrosis and the metabolic adaptations underlying their pathogenic responses remain unclear. Here, we report that a subset of mature B cells with heightened cytokine responses accumulate in the liver and promote inflammation in MASH. To meet the increased energetic demand of effector responses, B cells increase their ATP production via oxidative phosphorylation (OXPHOS) fueled by pyruvate oxidation in a B cell receptor (BCR)-specific manner. Blocking pyruvate oxidation completely abrogated the inflammatory capacity of MASH B cells. Accordingly, the restriction of the BCR led to MASH attenuation, including reductions in steatosis, hepatic inflammation, and fibrosis. Mechanistically, BCR restriction decreased B cell maturation, activation, and effector responses in the liver, accompanied by decreased T cell- and macrophage-mediated inflammation. Notably, attenuated liver fibrosis in BCR-restricted mice was associated with lower IgG production and decreased expression of Fc-gamma receptors on hepatic stellate cells. Together, these findings indicate a key role for B cell antigen-specific responses in promoting steatosis, inflammation, and fibrosis during MASH.

Identifiants

pubmed: 38014163
doi: 10.1101/2023.11.13.566832
pmc: PMC10680643
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : NIDDK NIH HHS
ID : R01 DK122056
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL155993
Pays : United States

Auteurs

Fanta Barrow (F)

Department of Integrative Biology & Physiology, University of Minnesota Medical School, Minneapolis MN 55455, USA.

Haiguang Wang (H)

Department of Integrative Biology & Physiology, University of Minnesota Medical School, Minneapolis MN 55455, USA.

Gavin Fredrickson (G)

Department of Integrative Biology & Physiology, University of Minnesota Medical School, Minneapolis MN 55455, USA.

Kira Florczak (K)

Department of Integrative Biology & Physiology, University of Minnesota Medical School, Minneapolis MN 55455, USA.

Erin Ciske (E)

Department of Integrative Biology & Physiology, University of Minnesota Medical School, Minneapolis MN 55455, USA.

Shalil Khanal (S)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA.

Preethy Parthiban (P)

Department of Integrative Biology & Physiology, University of Minnesota Medical School, Minneapolis MN 55455, USA.

Huy Nguyen (H)

Department of Integrative Biology & Physiology, University of Minnesota Medical School, Minneapolis MN 55455, USA.

Enrique Rios (E)

Department of Integrative Biology & Physiology, University of Minnesota Medical School, Minneapolis MN 55455, USA.

Enis Kostallari (E)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA.

Xavier S Revelo (XS)

Department of Integrative Biology & Physiology, University of Minnesota Medical School, Minneapolis MN 55455, USA.
Center for Immunology, University of Minnesota, Minneapolis MN 55455, USA.

Classifications MeSH